Total Payments
$21,370
2024 Payments
$2,981
Companies
81
Transactions
881
Medicare Patients
2,852
Medicare Billing
$414,504
Payment Breakdown by Category
Food & Beverage$13,753 (64.4%)
Consulting$4,500 (21.1%)
Education$1,622 (7.6%)
Travel$1,494 (7.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,753 | 806 | 64.4% |
| Consulting Fee | $4,500 | 1 | 21.1% |
| Education | $1,622 | 70 | 7.6% |
| Travel and Lodging | $1,494 | 4 | 7.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $6,772 | 39 | $0 (2024) |
| PFIZER INC. | $1,391 | 134 | $0 (2024) |
| Janssen Biotech, Inc. | $1,177 | 48 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $1,015 | 81 | $0 (2024) |
| Merck Sharp & Dohme LLC | $970.84 | 61 | $0 (2024) |
| Amgen Inc. | $924.59 | 53 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $896.21 | 53 | $0 (2024) |
| Genentech USA, Inc. | $754.18 | 49 | $0 (2024) |
| Astellas Pharma US Inc | $732.85 | 34 | $0 (2024) |
| Incyte Corporation | $464.12 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,981 | 126 | Janssen Biotech, Inc. ($556.43) |
| 2023 | $3,427 | 174 | Janssen Biotech, Inc. ($302.66) |
| 2022 | $2,399 | 110 | Incyte Corporation ($181.06) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $582.11 | 33 | Janssen Biotech, Inc. ($84.40) |
| 2019 | $2,541 | 198 | PFIZER INC. ($419.87) |
| 2018 | $8,577 | 180 | AstraZeneca Pharmaceuticals LP ($6,180) |
| 2017 | $849.40 | 59 | PFIZER INC. ($178.18) |
All Payment Transactions
881 individual payment records from CMS Open Payments — Page 1 of 36
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $29.75 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $26.82 | General |
| 12/09/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $27.38 | General |
| 12/05/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $30.75 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.01 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $29.45 | General |
| Category: Oncology | ||||||
| 11/27/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $22.77 | General |
| Category: Genetically Defined Disease | ||||||
| 11/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $2.90 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/25/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/22/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $19.20 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $106.05 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Food and Beverage | In-kind items and services | $23.61 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $23.27 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.31 | General |
| Category: Hematology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.26 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $5.61 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $19.29 | General |
| Category: HORMONE THERAPY | ||||||
| 11/12/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $16.04 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Food and Beverage | In-kind items and services | $28.31 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Aveo Pharmaceuticals, Inc. | FOTIVDA (Drug) | Education | In-kind items and services | $20.00 | General |
| Category: Oncology | ||||||
| 11/06/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $28.30 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $25.59 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 207 | 2,427 | $106,879 | $39,133 |
| 2022 | 1 | 11 | 21 | $5,985 | $2,163 |
| 2021 | 37 | 1,497 | 32,263 | $1.5M | $289,719 |
| 2020 | 23 | 1,137 | 2,935 | $341,644 | $83,489 |
Total Patients
2,852
Total Services
37,646
Medicare Billing
$414,504
Procedure Codes
71
All Medicare Procedures & Services
71 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 48 | 135 | $36,690 | $13,402 | 36.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 19 | 88 | $26,254 | $9,414 | 35.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 36 | $13,828 | $5,136 | 37.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 67 | $11,692 | $4,589 | 39.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $7,677 | $2,667 | 34.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $5,562 | $2,018 | 36.3% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 15 | 72 | $4,683 | $1,703 | 36.4% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 1,020 | $238.80 | $97.86 | 41.0% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 13 | 936 | $172.62 | $71.27 | 41.3% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 11 | 39 | $79.94 | $33.97 | 42.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 21 | $5,985 | $2,163 | 36.1% |
| J2505 | Injection, pegfilgrastim, 6 mg | Office | 2021 | 20 | 41 | $643,793 | $94,569 | 14.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 32 | 4,080 | $201,552 | $64,031 | 31.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 245 | 387 | $68,499 | $25,271 | 36.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 69 | 166 | $78,352 | $20,035 | 25.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 97 | 188 | $50,008 | $18,068 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 44 | 197 | $52,993 | $16,224 | 30.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 36 | 38 | $19,342 | $6,010 | 31.1% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2021 | 16 | 3,770 | $26,842 | $4,426 | 16.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 137 | 490 | $19,600 | $3,801 | 19.4% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 50 | 273 | $20,202 | $3,773 | 18.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 27 | $9,693 | $3,762 | 38.8% |
| 96521 | Refilling and maintenance of portable pump | Office | 2021 | 13 | 25 | $10,300 | $3,127 | 30.4% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 25 | 46 | $9,936 | $2,762 | 27.8% |
| 96417 | Infusion of different chemotherapy drug or substance into a vein up to 1 hour | Office | 2021 | 23 | 46 | $10,672 | $2,660 | 24.9% |
About Dr. Mohammed Sabbagh, MD
Dr. Mohammed Sabbagh, MD is a Hematology healthcare provider based in Georgetown, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1164420105.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mohammed Sabbagh, MD has received a total of $21,370 in payments from pharmaceutical and medical device companies, with $2,981 received in 2024. These payments were reported across 881 transactions from 81 companies. The most common payment nature is "Food and Beverage" ($13,753).
As a Medicare-enrolled provider, Sabbagh has provided services to 2,852 Medicare beneficiaries, totaling 37,646 services with total Medicare billing of $414,504. Data is available for 4 years (2020–2023), covering 71 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Georgetown, TX
- Active Since 07/13/2005
- Last Updated 10/02/2025
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1164420105
Products in Payments
- TAGRISSO (Drug) $6,168
- KEYTRUDA (Biological) $886.51
- IBRANCE (Drug) $654.07
- OPDIVO (Biological) $462.69
- ERLEADA (Drug) $438.73
- Kyprolis (Biological) $366.95
- XTANDI (Drug) $350.90
- Lenvima (Drug) $285.20
- ZEJULA (Drug) $262.81
- DARZALEX (Biological) $262.67
- JAKAFI (Drug) $222.51
- Cabometyx (Drug) $196.75
- IMBRUVICA (Drug) $187.29
- FOTIVDA (Drug) $181.14
- Nplate (Biological) $171.08
- CALQUENCE (Drug) $168.54
- Perjeta (Biological) $166.02
- SCEMBLIX (Drug) $163.40
- LYNPARZA (Drug) $157.09
- XALKORI (Drug) $156.59
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.